Jeffrey Skolnik

1.8k total citations
32 papers, 1.2k citations indexed

About

Jeffrey Skolnik is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffrey Skolnik has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffrey Skolnik's work include CAR-T cell therapy research (6 papers), Cancer-related Molecular Pathways (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Jeffrey Skolnik is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer-related Molecular Pathways (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Jeffrey Skolnik collaborates with scholars based in United States, United Kingdom and Spain. Jeffrey Skolnik's co-authors include Peter C. Adamson, Jeffrey S. Barrett, Dennis Huszar, Ronald Herbst, Maria‐Elena Theoclitou, Dimple Patel, Bhuvana Jayaraman, Michele Pagano, Giorgio Inghirami and Marco Chilosi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jeffrey Skolnik

31 papers receiving 1.2k citations

Peers

Countries citing papers authored by Jeffrey Skolnik

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Skolnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Skolnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Skolnik more than expected).

Fields of papers citing papers by Jeffrey Skolnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Skolnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Skolnik. The network helps show where Jeffrey Skolnik may publish in the future.

Co-authorship network of co-authors of Jeffrey Skolnik

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Skolnik. A scholar is included among the top collaborators of Jeffrey Skolnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Skolnik. Jeffrey Skolnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DNA Immunotherapy ( INO ‐3107) Results in Long‐Term Surgery Reduction in RRP 2025 ·The Laryngoscope ·Milan R. Amin, Peter C. Belafsky, Simon R. Best, Aaron D. Friedman, Adam M. Klein, David G. Lott, Ted Mau, Randal C. Paniello, Seth M. Pransky, Nabil F. Saba, Christopher Welsh, (unknown), Elisabeth Gillespie, Michael Dallas, Matthew P. Morrow, Jeffrey Skolnik	1
2	Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations. 2025 ·Journal of Clinical Oncology ·Susan M. Domchek, Alexandra Torres, (unknown), Joann M. Miller, (unknown), (unknown), (unknown), Payal D. Shah, Matthew P. Morrow, Jeffrey Skolnik, Robert H. Vonderheide	0
3	Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors 2021 ·Journal for ImmunoTherapy of Cancer ·Robert H. Vonderheide, Kimberly A. Kraynyak, Anthony F. Shields, Autumn J. McRee, Jennifer M. Johnson, Weijing Sun, Ashish V. Chintakuntlawar, Jan M. Pawlicki, Albert J. Sylvester, Trevor McMullan, Robert J. Samuels, Joseph Kim, David B. Weiner, Jean Boyer, Matthew P. Morrow, Laurent Humeau, Jeffrey Skolnik	36
4	Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1 2021 ·Cancer Chemotherapy and Pharmacology ·Jeffrey Skolnik, David Hall, Donald A. Barkauskas, Ganesh S. Moorthy, Thomas R. Larson, Elizabeth Fox, Brenda J. Weigel, Stacey L. Berg, Joel M. Reid	7
5	Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis 2020 ·Vaccines ·Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert J. Sylvester, Jocelyn Cheung, (unknown), Véronique Schulten, Dawson Knoblock, Elisabeth Gillespie, Joshua Bauml, Jian Yan, Malissa Diehl, Jean Boyer, Michael Dallas, J Joseph Kim, David B. Weiner, Jeffrey Skolnik	20
6	P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM) 2020 ·Poster presentations ·Jeffrey Skolnik, David A. Reardon, Steven Brem, Arati Desai, Stephen Bagley, Sylvia C. Kurz, Macarena de la Fuente, Seema Nagpal, Mary Welch, (unknown), (unknown), (unknown), Israel Lowy, Kimberly A. Kraynyak, Matthew P. Morrow, Trevor McMullan, Jean Boyer	3
7	Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma 2019 ·Cancer Research ·Jeffrey Skolnik, Noah M. Hahn, Joaquim Bellmunt, (unknown), Malissa Diehl, Matthew P. Morrow, Kimberly A. Kraynyak, Trevor McMullan	1
8	A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer. 2018 ·Journal of Clinical Oncology ·Yasmin Hasan, Michael T. Spiotto, Larissa V. Furtado, Ana I. Tergas, Nita K. Lee, Rebecca Brooks, Anne R. McCall, Daniel W. Golden, Shruti Jolly, Gini F. Fleming, Matthew P. Morrow, Jeffrey Skolnik, Mark T. Esser, (unknown), Ralph R. Weichselbaum	4
9	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2015 ·European Journal of Cancer ·Ian W. Flinn, Nancy L. Bartlett, Kristie A. Blum, Kirit M. Ardeshna, Ann S. LaCasce, Christopher R. Flowers, Andrei R. Shustov, Kenneth S. Thress, Pat Mitchell, (unknown), Jeffrey Skolnik, Jonathan W. Friedberg	61
10	Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer 2014 ·European Journal of Cancer ·Gilles Vassal, Raphaël F. Rousseau, P. Blanc, Lucas Moreno, (unknown), (unknown), Martin Schrappe, Jeffrey Skolnik, (unknown), M. Brigid Bradley‐Garelik, Vaskar Saha, (unknown), H. Zwierzina	51
11	Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer 2013 ·Investigational New Drugs ·Robert J. Jones, Jacqueline Vuky, Tony Elliott, Graham M. Mead, José Ángel Arranz, John Chester, Simon Chowdhury, Arkadiusz Z. Dudek, (unknown), Marc‐Oliver Grimm, Jürgen E. Gschwend, Christian Wülfing, Peter Albers, Jianguo Li, Anna Osmukhina, Jeffrey Skolnik, Gary R. Hudes	34
12	Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients 2013 ·The AAPS Journal ·Jeffrey S. Barrett, Dimple Patel, (unknown), Gaurav Bajaj, Jeffrey Skolnik	14
13	A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies 2012 ·Investigational New Drugs ·John F. Gerecitano, Joe Stephenson, Nancy Lewis, Anna Osmukhina, (unknown), Kaida Wu, (unknown), Dennis Huszar, Jeffrey Skolnik, Gary K. Schwartz	30
14	A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors 2011 ·Cancer Chemotherapy and Pharmacology ·Jeffrey R. Infante, Razelle Kurzrock, Jennifer L. Spratlin, Howard A. Burris, Sabine Eckhardt, (unknown), Kang Wu, Jeffrey Skolnik, (unknown), Anna Osmukhina, Dennis Huszar, Ronald Herbst	31
15	A Reliable and Safe Method of Collecting Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations 2011 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Sabrina Boodhan, (unknown), (unknown), (unknown), (unknown), (unknown), Jeffrey Skolnik, L. Lee Dupuis	6
16	Dactinomycin and vincristine toxicity in the treatment of childhood cancer: A retrospective study from the Children's Oncology Group 2010 ·Pediatric Blood & Cancer ·Bryan Langholz, Jeffrey Skolnik, Jeffrey S. Barrett, Jamie L. Renbarger, Nita L. Seibel, Anne Zajicek, Carola A.S. Arndt	43
17	Kinesin motor proteins as targets for cancer therapy 2009 ·Cancer and Metastasis Reviews ·Dennis Huszar, Maria‐Elena Theoclitou, Jeffrey Skolnik, Ronald Herbst	170
18	A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation 2008 ·Computer Methods and Programs in Biomedicine ·Jeffrey S. Barrett, Bhuvana Jayaraman, Dimple Patel, Jeffrey Skolnik	10
19	A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer 2005 ·Cancer Chemotherapy and Pharmacology ·Jeffrey Skolnik, Jeffrey S. Barrett, (unknown), Peter C. Adamson	30
20	S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase 2002 ·American Journal Of Pathology ·Roberto Chiarle, Yan Fan, Roberto Piva, (unknown), Jeffrey Skolnik, Domenico Novero, Giorgio Palestro, Chris De Wolf‐Peeters, Marco Chilosi, Michele Pagano, Giorgio Inghirami	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact